Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

3 Jul 2015
Change (% chg)

Rs40.05 (+1.13%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for REDY.NS


Dr.Reddy's Laboratories Ltd is an India-based integrated global pharmaceutical company that provides medicines. The Company derives its revenue from the sale of finished dosage forms, active pharmaceutical ingredients and intermediates, development and manufacturing services provided to pharmaceutical and biotechnology... (more)


Beta: 0.32
Market Cap(Mil.): Rs611,919.19
Shares Outstanding(Mil.): 170.56
Dividend: 20.00
Yield (%): 0.56


  REDY.NS Industry Sector
P/E (TTM): 174.43 35.83 39.81
EPS (TTM): 20.57 -- --
ROI: -- 17.03 16.23
ROE: -- 17.93 17.36
Search Stocks

BUZZ-Australia's Alchemia hits record low

** Drug developer Alchemia Ltd slumps as much as 57.8 pct to a record low of A$0.035

29 May 2015

BUZZ-India's Dr.Reddy's up on hopes of US FDA resolution of Srikakulam plant

** The generic drug maker remains confident of a faster resolution of US FDA observations at the Srikakulam plant - CLSA

31 Mar 2015

BUZZ-India's Dr.Reddy's rises on agreement to market new drug

** Shares of Indian pharmaceutical company Dr.Reddy's Laboratories Ltd gain 1.1 pct

24 Mar 2015

BUZZ-Investors take tactical refuge in Indian pharma ahead of Fed

** Pharmaceutical stocks, traditionally seen as defensives, gain on churning ahead of the U.S. Federal Reserve policy meeting outcome on Wednesday

17 Mar 2015

Dr.Reddy's in talks to buy UCB India business for $135 mln - source

MUMBAI, March 10 - Indian drugmaker Dr.Reddy's Laboratories Ltd is in talks to acquire the Indian operations of Belgian pharmaceutical company UCB SA for about $135 million, said a person with direct knowledge of the matter.

10 Mar 2015

Indian shares continue to fall ahead of RBI review

MUMBAI, Feb 2 - Indian shares fell on Monday, continuing their retreat from record highs hit last week as blue-chips including Dr.Reddy's Laboratories extended falls after disappointing earnings, while caution prevailed a day before the central bank's policy review.

02 Feb 2015

BUZZ-India's Dr Reddy's falls; Credit Suisse cuts to "neutral"

** Delay in monetisation of key drugs such as Nexium and Copaxone, which implies low-teen FY16 EPS growth - Credit Suisse

30 Jan 2015

Earnings vs. Estimates

Search Stocks